HF Gene-Therapy Trial CUPID-2 Fails to Meet Primary End Point: Top-Line Results

April 29, 2015

SAN DIEGO, CA — Despite earlier promise in a small dose-finding study, a novel gene-based, single-dose treatment for heart failure failed to make a significant difference in a primary end point reflecting recurrent HF events in a placebo-controlled phase 2b trial with several hundred participants, the sponsor, Celladon, has announced[1].

The study, CUPID-2b, explored intracoronary delivery of a gene tied to myocardial contraction and relaxation through regulation of intracellular calcium, AAV1/SERCA2a (Mydicar), in patients with NYHA 2-4 systolic heart failure despite optimal drug and device therapy.

The therapy seemed to improve symptoms, functional status, and ventricular volumes in the 39-patient first-in-human CUPID study, presented at Heart Failure Congress 2010 and covered then by heartwire from Medscape.

In the CUPID 2b 243-patient intention-to-treat population, the hazard ratio on active therapy for the primary end point, a composite of HF hospitalization or ambulatory treatment for worsening heart failure at 12 months, was 0.93 (95% CI 0.53-1.65, P=0.81).

There were no significant effects for secondary end points including death from any cause, need for a mechanical circulatory support device or heart transplant, and improvement in NYHA class, 6-minute walk test, or quality of life. "No safety issues were noted," according to the company announcement.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.